Sign in
Taking peoplePhase 3

Bevacizumab compared with dexamethasone for brain damage after radiation treatment

Compares bevacizumab with dexamethasone for radiation necrosis after treatment for glioma or brain metastases.

Key facts

Who runs it
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Where
Netherlands7 sites in 1 countryChoose a country to see its sites
Registry title
Bevacizumab for the treatment of cerebral RAdiation Induced NecrosiS (BRAINS) study: A multicenter, open-label, randomized clinical trial to assess the clinical efficacy and cost-effectiveness of bevacizumab versus corticosteroids as first-line treatment in patients with symptomatic cerebral radiation necrosis after radiation for high grade glioma or brain metastases
Status
Recruiting
Phase
Phase 3
People taking part
408 people, planned
Started
10 Jul 2025
Expected to end
1 May 2029
Type of study
Interventional
Record updated
6 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with high grade glioma or brain metastases who have symptoms from brain tissue damage caused by radiation (radiation necrosis). It compares bevacizumab with dexamethasone as the first treatment.

Age
18 years or older
Sex
All sexes
Disease stage
A new episode of symptomatic radiation necrosis after focal (re-)irradiation, confirmed by the local neuro-oncology board. KPS score ≤ 90, plus loss of at least one point on the NANO scale or a lasting headache from the necrosis. Glioma: high-grade diffuse glioma by WHO 2021 criteria (grade 3-4). Brain metastases: from a solid tumor, at least 3 months after radiation, with no sign of tumor growth.
Earlier treatment
Must have had focal radiation or re-radiation to the brain. No bevacizumab in the 3 months before randomization. Limits on earlier dexamethasone: on average ≤1.5 mg/day in the 4 weeks before the last 4 weeks; higher doses are allowed in the last 4 weeks. No high-dose dexamethasone (≥ 4 mg/day for ≥ 3 weeks) for this lesion in the 6 months before, apart from the last 8 weeks.
Biomarker or test result
For glioma: confirmed tissue diagnosis, for example astrocytoma IDH-mutant or IDH-wildtype, oligodendroglioma with 1p/19q codeletion, or glioblastoma IDH-wildtype.

Main reasons for not taking part

  • Life expectancy under 3 months
  • Signs of brain swelling that need urgent surgery
  • Allergy to bevacizumab or dexamethasone, or poor kidney function (creatinine clearance <30 mL/min)
  • Serious heart or blood vessel disease, bleeding history or high bleeding risk
  • Pregnancy or breastfeeding

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Age ≥ 18 years old
  • Only for HGG patients: No minimum time interval between diagnosis of pseudoprogression/sCRN and completion of focal (re-) irradiation
  • Only for HGG patients: A working diagnosis of pseudoprogression/CRN is required
  • Episode of sCRN after completion of focal (re-)irradiation, as determined by the local Multidisciplinary Neuro-Oncology Board. Patients with a previously treated sCRN lesion may be included provided that they develop a new, distinct episode of sCRN
  • KPS score ≤ 90 and either (a) a minimum loss of one point on the Neurologic Assessment in Neuro-Oncology (NANO) scale as compared to the maximum score of 23 points due to sCRN, or (b) a persisting headache attributable to sCRN
  • Able to understand the patient information, online tests and questionnaires
  • Written informed consent
  • Only for BM patients: BM of solid tumor, including all primary tumor types
  • Only for HGG patients: A confirmed histological diagnosis of high-grade diffuse glioma according to WHO 2021 criteria, including: astrocytoma, IDH-mutant, grade 3-4; astrocytoma, IDH-wildtype (sybtype molecular glioblastoma); oligodendroglioma, 1p/19q codeleted, grade 3; diffuse glioma, NEC, grade 3-4; or glioblastoma, IDH-wildtype, grade 4
  • Only for BM patients: Time interval of ≥ 3 months between diagnosis of sCRN and completion of focal (re-)irradiation
  • Only for BM patients: A working diagnosis of CRN without evidence of a combination with tumor progression is required

Who cannot take part

  • Dexamethasone use prior to randomization o In 4 weeks prior to the 4 weeks of permitted higher (>1.5 mg/day) dosing of dexamethasone: average daily dose of dexamethasone (or an equivalent dose of an alternative corticosteroid) ≤1.5 mg/day over this 4-week period. o 4 weeks directly prior to randomization: higher average daily doses of dexamethasone (or an equivalent dose of an alternative corticosteroid)(> 1.5 mg/day) is permitted
  • Impending radiological or clinical signs of brain herniation necessitating immediate decompressive surgery
  • Prior treatment with bevacizumab <3 months before randomization
  • Previous treatment with high-dose dexamethasone (≥ 4 mg/day for ≥ 3 weeks) for the sCRN lesion within the 6 months prior to randomization, excluding the 8 weeks immediately preceding randomization, is not permitted
  • Any comorbidity or condition that prevents safe administration of the studied medication, determined by the treating physician, including but not limited to: a. Intolerance for murine proteins b. Hypersensitivity or allergy to the active substance or to any of the excipients of bevacizumab or dexamethasone c. Nephrotic syndrome or abnormal renal function o Calculated (Cockcroft-Gault) or measured creatinine clearance <30 mL/min; proteinuria will be evaluated according to local protocol. Patients exceeding the locally defined threshold at baseline should undergo 24 hours urine collection and must demonstrate ≤ 1 g of protein/24 hr. d. Clinical significant cardiovascular disease o Uncontrolled hypertension (systolic BP >150mmHg and/or diastolic >100mmHg) despite the use of ≥ 3 antihypertensive drugs o Previous hypertensive crisis, hypertensive encephalopathy or previous reversible posterior leukoencephalopathy syndrome (RPLS) o Non-tumor-related vascular events:  cerebral or cardiac ischemia or peripheral artery disease < 3 months before randomization  Deep venous thrombosis, lung embolism < 6 weeks before randomization. Patients are allowed if deep venous thrombosis, lung embolism occurs > 6 weeks before randomization and are adequately treated with anticoagulants. o History of aortic aneurysm or dissection o Congestive heart failure NYHA II-IV e. History of gastro-intestinal fistula, perforation or abscess < 6 months f. History of bleeding g. Excess risk of bleeding i. High-dose radiotherapy to the mediastinum, abdomen, or lower pelvis; administration of bevacizumab should only be considered after prior consultation with a pulmonologist or oncologist j. Pregnancy or lactation. Women of child bearing potential (WOCBP) must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 7 days prior to randomization. WOCBP and female partners of male patients must comply with adequate contraception methods as requested by the study protocol k. Evidence of any other medical conditions (such as psychiatric illness, physical examination or laboratory findings) that may interfere with the study treatment, affect patient compliance or place the patient at high risk for treatment-related complications according to the treating physician l. Current or recent (within 30 days of first study treatment) treatment with another investigational drug
  • Life expectancy <3 months

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To compare the clinical efficacy of first-line bevacizumab vs dexamethasone for cerabral radiation necrosis (sCRN) in high grade glioma (HGG) and brain metastases (BM) patients

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Bevacizumab for the treatment of cerebral RAdiation Induced NecrosiS (BRAINS) study: A multicenter, open-label, randomized clinical trial to assess the clinical efficacy and cost-effectiveness of bevacizumab versus corticosteroids as first-line treatment in patients with symptomatic cerebral radiation necrosis after radiation for high grade glioma or brain metastases
Plain-language title
Bevacizumab compared with dexamethasone for brain damage after radiation treatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
6 November 2026